CBS and neoplasm: Evidence level: preclinical and dominant signals: CBS/CSE/3-MST overexpression, tumor “sulfur addiction”, and xenograft sensitivity to enzyme inhibition (e.g., AOAA) or high-load donors (e.g., GYY4137).